このページの翻訳は実験的なもので、現在開発中です。お待ちしております！
Charles River Laboratories International バランスシートの健全性
財務の健全性 基準チェック /46
Charles River Laboratories Internationalの総株主資本は$3.7B 、総負債は$2.6Bで、負債比率は71.1%となります。総資産と総負債はそれぞれ$8.2Bと$4.4Bです。 Charles River Laboratories Internationalの EBIT は$627.2Mで、利息カバレッジ比率4.8です。現金および短期投資は$327.0Mです。
主要情報
71.1%
負債資本比率
US$2.63b
負債
| インタレスト・カバレッジ・レシオ | 4.8x |
| 現金 | US$327.04m |
| エクイティ | US$3.70b |
| 負債合計 | US$4.45b |
| 総資産 | US$8.15b |
財務の健全性に関する最新情報
Charles River Laboratories International (NYSE:CRL) Has A Pretty Healthy Balance Sheet
Mar 27
Charles River Laboratories International (NYSE:CRL) Has A Somewhat Strained Balance Sheet
Oct 27Charles River Laboratories International (NYSE:CRL) Seems To Use Debt Quite Sensibly
Jul 03These 4 Measures Indicate That Charles River Laboratories International (NYSE:CRL) Is Using Debt Reasonably Well
Apr 02We Think Charles River Laboratories International (NYSE:CRL) Can Stay On Top Of Its Debt
Dec 28Recent updates
Charles River Laboratories: Fair Valuation Against Fundamentals
May 31What Is Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Doing?
May 25Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 30% Discount?
Apr 27Charles River Laboratories International, Inc.'s (NYSE:CRL) Price Is Out Of Tune With Earnings
Apr 11Charles River Laboratories International (NYSE:CRL) Has A Pretty Healthy Balance Sheet
Mar 27Charles River Laboratories International (NYSE:CRL) Strong Profits May Be Masking Some Underlying Issues
Feb 21Charles River Laboratories: Weak Biopharma Spending Is Transitory; Initiate With 'Hold'
Feb 16Is It Time To Consider Buying Charles River Laboratories International, Inc. (NYSE:CRL)?
Jan 17Charles River Laboratories International, Inc.'s (NYSE:CRL) Share Price Not Quite Adding Up
Jan 02Charles River Laboratories International (NYSE:CRL) Ticks All The Boxes When It Comes To Earnings Growth
Dec 17Charles River Laboratories: Mr. Market Went From Overvaluation To Undervaluation
Nov 26Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 29% Discount?
Nov 12Charles River: Q3 Points To Ongoing Deterioration
Nov 09Charles River Laboratories International (NYSE:CRL) Has A Somewhat Strained Balance Sheet
Oct 27At US$197, Is Charles River Laboratories International, Inc. (NYSE:CRL) Worth Looking At Closely?
Oct 12Charles River Laboratories: Diving Into The Lab (Rating Upgrade)
Oct 06Is Charles River Laboratories International, Inc. (NYSE:CRL) Trading At A 27% Discount?
Aug 10Charles River Laboratories: Very Attractive After The Pullback
Jul 26Does Charles River Laboratories International (NYSE:CRL) Deserve A Spot On Your Watchlist?
Jul 22Charles River Laboratories International (NYSE:CRL) Seems To Use Debt Quite Sensibly
Jul 03When Should You Buy Charles River Laboratories International, Inc. (NYSE:CRL)?
Jun 19A Look At The Intrinsic Value Of Charles River Laboratories International, Inc. (NYSE:CRL)
May 01Should You Be Adding Charles River Laboratories International (NYSE:CRL) To Your Watchlist Today?
Apr 16These 4 Measures Indicate That Charles River Laboratories International (NYSE:CRL) Is Using Debt Reasonably Well
Apr 02Is Charles River Laboratories International, Inc. (NYSE:CRL) Potentially Undervalued?
Mar 19Charles River gains as Guggenheim upgrades despite post-earnings selloff
Feb 23Charles River Laboratories International: A Great Business At A Decent Price
Feb 06Charles River acquires SAMDI Tech for $50M in cash
Jan 30Is Charles River Laboratories International, Inc. (NYSE:CRL) Worth US$253 Based On Its Intrinsic Value?
Jan 24If EPS Growth Is Important To You, Charles River Laboratories International (NYSE:CRL) Presents An Opportunity
Jan 10Charles River Laboratories sells Avian Vaccine Services business to Arlington Capital
Jan 05We Think Charles River Laboratories International (NYSE:CRL) Can Stay On Top Of Its Debt
Dec 28Is Charles River Laboratories International, Inc. (NYSE:CRL) Potentially Undervalued?
Dec 14財務状況分析
短期負債: CRLの 短期資産 ( $1.7B ) が 短期負債 ( $954.8M ) を超えています。
長期負債: CRLの短期資産 ( $1.7B ) は 長期負債 ( $3.5B ) をカバーしていません。
デット・ツー・エクイティの歴史と分析
負債レベル: CRLの 純負債対資本比率 ( 62.3% ) は 高い と見なされます。
負債の削減: CRLの負債対資本比率は、過去 5 年間で108.5%から71.1%に減少しました。
債務返済能力: CRLの負債は 営業キャッシュフロー によって 十分にカバー されています ( 26.8% )。
インタレストカバレッジ: CRLの負債に対する 利息支払い は EBIT ( 4.8 x coverage) によって 十分にカバーされています。